The relationship between Helicobacter pylori seropositivity and COPD

Marc A. Sze, Yu Wei Roy Chen, Sheena Tam, Donald Tashkin, Robert A Wise, John E. Connett, SF Paul Man, Don D. Sin

Research output: Contribution to journalArticle

Abstract

Rationale: Chronic systemic infections such as those with Helicobacter pylori (H. pylori) may contribute to the evolution and progression of chronic obstructive pulmonary disease (COPD). Using data from the Lung Health Study (LHS), we determined the relationship of H. pylori infection with the severity and progression of COPD. Methods: Using an immunoassay, we measured H. pylori immunoglobulin G (IgG) antibody titres in serum samples of 4765 patients with mild-to-moderate COPD. We then determined their relationship with the individual's FEV1 and the rate of decline in FEV1 and mortality over 11 years using multiple regression analysis. Results: Approximately 18% of the patients were seropositive to H. pylori and these individuals demonstrated lower FEV1 (L) values at every study visit compared with individuals who were seronegative for H. pylori (p value=0.00012). However, patients with seropositivity to H. pylori were on average 0.012 m shorter than those with seronegativity (p value=0.0015). The significant relationship between FEV1 and H. pylori seropositivity disappeared when FEV1 per cent predicted (FEV1pp) was used (p value=0.45). H. pylori seropositive individuals had greater circulating C reactive protein (CRP) levels compared with H. pylori seronegative individuals (p value=0.012), and had increased risk of cardiovascular mortality (relative risk 1.61, p=0.05). Conclusions H. pylori infection was associated with reduced lung function that is most likely due to the effect of the bacterium on lung growth earlier in life. It is also associated with systemic inflammation and increased risk of cardiovascular mortality in patients with COPD. Trial registration numbers: NCT00000568 and NCT00000569.

Original languageEnglish (US)
Pages (from-to)923-929
Number of pages7
JournalThorax
Volume70
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Helicobacter pylori
Chronic Obstructive Pulmonary Disease
Helicobacter Infections
Lung
Mortality
Immunoassay
C-Reactive Protein
Immunoglobulin G
Regression Analysis
Inflammation
Bacteria
Antibodies
Health
Growth
Infection
Serum

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Sze, M. A., Roy Chen, Y. W., Tam, S., Tashkin, D., Wise, R. A., Connett, J. E., ... Sin, D. D. (2015). The relationship between Helicobacter pylori seropositivity and COPD. Thorax, 70(10), 923-929. https://doi.org/10.1136/thoraxjnl-2015-207059

The relationship between Helicobacter pylori seropositivity and COPD. / Sze, Marc A.; Roy Chen, Yu Wei; Tam, Sheena; Tashkin, Donald; Wise, Robert A; Connett, John E.; Man, SF Paul; Sin, Don D.

In: Thorax, Vol. 70, No. 10, 01.10.2015, p. 923-929.

Research output: Contribution to journalArticle

Sze, MA, Roy Chen, YW, Tam, S, Tashkin, D, Wise, RA, Connett, JE, Man, SFP & Sin, DD 2015, 'The relationship between Helicobacter pylori seropositivity and COPD', Thorax, vol. 70, no. 10, pp. 923-929. https://doi.org/10.1136/thoraxjnl-2015-207059
Sze MA, Roy Chen YW, Tam S, Tashkin D, Wise RA, Connett JE et al. The relationship between Helicobacter pylori seropositivity and COPD. Thorax. 2015 Oct 1;70(10):923-929. https://doi.org/10.1136/thoraxjnl-2015-207059
Sze, Marc A. ; Roy Chen, Yu Wei ; Tam, Sheena ; Tashkin, Donald ; Wise, Robert A ; Connett, John E. ; Man, SF Paul ; Sin, Don D. / The relationship between Helicobacter pylori seropositivity and COPD. In: Thorax. 2015 ; Vol. 70, No. 10. pp. 923-929.
@article{e7144cb1c51845758ba4b53bb8ca463a,
title = "The relationship between Helicobacter pylori seropositivity and COPD",
abstract = "Rationale: Chronic systemic infections such as those with Helicobacter pylori (H. pylori) may contribute to the evolution and progression of chronic obstructive pulmonary disease (COPD). Using data from the Lung Health Study (LHS), we determined the relationship of H. pylori infection with the severity and progression of COPD. Methods: Using an immunoassay, we measured H. pylori immunoglobulin G (IgG) antibody titres in serum samples of 4765 patients with mild-to-moderate COPD. We then determined their relationship with the individual's FEV1 and the rate of decline in FEV1 and mortality over 11 years using multiple regression analysis. Results: Approximately 18{\%} of the patients were seropositive to H. pylori and these individuals demonstrated lower FEV1 (L) values at every study visit compared with individuals who were seronegative for H. pylori (p value=0.00012). However, patients with seropositivity to H. pylori were on average 0.012 m shorter than those with seronegativity (p value=0.0015). The significant relationship between FEV1 and H. pylori seropositivity disappeared when FEV1 per cent predicted (FEV1pp) was used (p value=0.45). H. pylori seropositive individuals had greater circulating C reactive protein (CRP) levels compared with H. pylori seronegative individuals (p value=0.012), and had increased risk of cardiovascular mortality (relative risk 1.61, p=0.05). Conclusions H. pylori infection was associated with reduced lung function that is most likely due to the effect of the bacterium on lung growth earlier in life. It is also associated with systemic inflammation and increased risk of cardiovascular mortality in patients with COPD. Trial registration numbers: NCT00000568 and NCT00000569.",
author = "Sze, {Marc A.} and {Roy Chen}, {Yu Wei} and Sheena Tam and Donald Tashkin and Wise, {Robert A} and Connett, {John E.} and Man, {SF Paul} and Sin, {Don D.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1136/thoraxjnl-2015-207059",
language = "English (US)",
volume = "70",
pages = "923--929",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - The relationship between Helicobacter pylori seropositivity and COPD

AU - Sze, Marc A.

AU - Roy Chen, Yu Wei

AU - Tam, Sheena

AU - Tashkin, Donald

AU - Wise, Robert A

AU - Connett, John E.

AU - Man, SF Paul

AU - Sin, Don D.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Rationale: Chronic systemic infections such as those with Helicobacter pylori (H. pylori) may contribute to the evolution and progression of chronic obstructive pulmonary disease (COPD). Using data from the Lung Health Study (LHS), we determined the relationship of H. pylori infection with the severity and progression of COPD. Methods: Using an immunoassay, we measured H. pylori immunoglobulin G (IgG) antibody titres in serum samples of 4765 patients with mild-to-moderate COPD. We then determined their relationship with the individual's FEV1 and the rate of decline in FEV1 and mortality over 11 years using multiple regression analysis. Results: Approximately 18% of the patients were seropositive to H. pylori and these individuals demonstrated lower FEV1 (L) values at every study visit compared with individuals who were seronegative for H. pylori (p value=0.00012). However, patients with seropositivity to H. pylori were on average 0.012 m shorter than those with seronegativity (p value=0.0015). The significant relationship between FEV1 and H. pylori seropositivity disappeared when FEV1 per cent predicted (FEV1pp) was used (p value=0.45). H. pylori seropositive individuals had greater circulating C reactive protein (CRP) levels compared with H. pylori seronegative individuals (p value=0.012), and had increased risk of cardiovascular mortality (relative risk 1.61, p=0.05). Conclusions H. pylori infection was associated with reduced lung function that is most likely due to the effect of the bacterium on lung growth earlier in life. It is also associated with systemic inflammation and increased risk of cardiovascular mortality in patients with COPD. Trial registration numbers: NCT00000568 and NCT00000569.

AB - Rationale: Chronic systemic infections such as those with Helicobacter pylori (H. pylori) may contribute to the evolution and progression of chronic obstructive pulmonary disease (COPD). Using data from the Lung Health Study (LHS), we determined the relationship of H. pylori infection with the severity and progression of COPD. Methods: Using an immunoassay, we measured H. pylori immunoglobulin G (IgG) antibody titres in serum samples of 4765 patients with mild-to-moderate COPD. We then determined their relationship with the individual's FEV1 and the rate of decline in FEV1 and mortality over 11 years using multiple regression analysis. Results: Approximately 18% of the patients were seropositive to H. pylori and these individuals demonstrated lower FEV1 (L) values at every study visit compared with individuals who were seronegative for H. pylori (p value=0.00012). However, patients with seropositivity to H. pylori were on average 0.012 m shorter than those with seronegativity (p value=0.0015). The significant relationship between FEV1 and H. pylori seropositivity disappeared when FEV1 per cent predicted (FEV1pp) was used (p value=0.45). H. pylori seropositive individuals had greater circulating C reactive protein (CRP) levels compared with H. pylori seronegative individuals (p value=0.012), and had increased risk of cardiovascular mortality (relative risk 1.61, p=0.05). Conclusions H. pylori infection was associated with reduced lung function that is most likely due to the effect of the bacterium on lung growth earlier in life. It is also associated with systemic inflammation and increased risk of cardiovascular mortality in patients with COPD. Trial registration numbers: NCT00000568 and NCT00000569.

UR - http://www.scopus.com/inward/record.url?scp=84942155634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942155634&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2015-207059

DO - 10.1136/thoraxjnl-2015-207059

M3 - Article

VL - 70

SP - 923

EP - 929

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 10

ER -